Mirati Therapeutics is set to reveal the first clinical data on its closely watched KRAS G12C inhibitor MRTX849 Oct. 28. The readout is a key moment in the fairly short history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.
